Overview

Dose-Response and Variability of Inhaled Insulin in Type 2 Diabetes

Status:
Completed
Trial end date:
2014-01-01
Target enrollment:
Participant gender:
Summary
Pharmacokinetic (PK) and Pharmacodynamic (PD) dose-response investigation of Dance-501 inhaled human insulin
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Dance Biopharm Inc.
Treatments:
Insulin
Insulin Lispro
Insulin, Globin Zinc